PL3529236T4 - Krystaliczne formy erawacykliny - Google Patents

Krystaliczne formy erawacykliny

Info

Publication number
PL3529236T4
PL3529236T4 PL17794505.2T PL17794505T PL3529236T4 PL 3529236 T4 PL3529236 T4 PL 3529236T4 PL 17794505 T PL17794505 T PL 17794505T PL 3529236 T4 PL3529236 T4 PL 3529236T4
Authority
PL
Poland
Prior art keywords
eravacycline
crystalline forms
crystalline
forms
Prior art date
Application number
PL17794505.2T
Other languages
English (en)
Other versions
PL3529236T3 (pl
Inventor
Danny LAFRANCE
Philip C. Hogan
Yansheng Liu
Minsheng He
Chi-Li Chen
John Niu
Original Assignee
Tetraphase Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tetraphase Pharmaceuticals, Inc. filed Critical Tetraphase Pharmaceuticals, Inc.
Publication of PL3529236T4 publication Critical patent/PL3529236T4/pl
Publication of PL3529236T3 publication Critical patent/PL3529236T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL17794505.2T 2016-10-19 2017-10-19 Krystaliczne formy erawacykliny PL3529236T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662410230P 2016-10-19 2016-10-19
PCT/US2017/057385 WO2018075767A1 (en) 2016-10-19 2017-10-19 Crystalline forms of eravacycline

Publications (2)

Publication Number Publication Date
PL3529236T4 true PL3529236T4 (pl) 2024-07-08
PL3529236T3 PL3529236T3 (pl) 2024-07-08

Family

ID=60263035

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17794505.2T PL3529236T3 (pl) 2016-10-19 2017-10-19 Krystaliczne formy erawacykliny

Country Status (15)

Country Link
US (4) US10961190B2 (pl)
EP (1) EP3529236B1 (pl)
JP (2) JP7492335B2 (pl)
KR (2) KR102880712B1 (pl)
CN (2) CN117903083A (pl)
DK (1) DK3529236T3 (pl)
ES (1) ES2978198T3 (pl)
HR (1) HRP20240605T1 (pl)
HU (1) HUE066360T2 (pl)
MA (1) MA46567A (pl)
PH (1) PH12019500822B1 (pl)
PL (1) PL3529236T3 (pl)
SG (1) SG11201903327PA (pl)
SI (1) SI3529236T1 (pl)
WO (1) WO2018075767A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201902057T4 (tr) 2012-08-31 2019-03-21 Tetraphase Pharmaceuticals Inc Tetrasiklin bileşikleri.
WO2017125557A1 (en) 2016-01-22 2017-07-27 Sandoz Ag Crystalline eravacycline bis-hydrochloride
MA46567A (fr) * 2016-10-19 2019-08-28 Tetraphase Pharmaceuticals Inc Formes cristallines de l'éravacycline
WO2020097450A1 (en) 2018-11-09 2020-05-14 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a compound and uses thereof
EP4531866A4 (en) * 2022-05-29 2026-06-17 B G Negev Technologies And Applications Ltd At Ben Gurion Univ ERAVACYCLINE FOR CANCER TREATMENT
CN115006411A (zh) * 2022-07-26 2022-09-06 中南大学湘雅医院 依拉环素类化合物的应用、药物及其制备方法

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB935384A (en) 1959-03-30 1963-08-28 Pfizer & Co C Tetracycline derivatives and preparation thereof
US3338963A (en) 1960-10-28 1967-08-29 American Cyanamid Co Tetracycline compounds
GB1034933A (en) 1962-10-29 1966-07-06 American Cyanamid Co 4-demethylamino-4-substituted amino 6-demethyl tetracyclines
US3364123A (en) 1963-05-06 1968-01-16 Squibb & Sons Inc Production of 4n-demethyl-4n-ethyl tetracyclines
USRE26253E (en) 1963-05-17 1967-08-15 And z-alkylamino-g-deoxytetracycline
GB1065715A (en) 1964-04-16 1967-04-19 Pfizer & Co C Tetracycline derivatives
US3247226A (en) 1964-07-06 1966-04-19 American Cyanamid Co 4-dimethylamino and 4-hydroxytetracycloxides
US3394178A (en) 1965-01-26 1968-07-23 Merck & Co Inc Nu-ethyloxytetracycline
GB1077598A (en) 1965-05-12 1967-08-02 Pfizer & Co C Preparation of n-demethyl tetracyclines
US3304227A (en) 1965-07-15 1967-02-14 Loyal E Loveless Antibiotic-containing animal feed
US3433709A (en) 1965-12-07 1969-03-18 American Cyanamid Co Biological transformation of alpha-6-deoxytetracyclines to tetracyclines
US3849493A (en) 1966-08-01 1974-11-19 Pfizer D-ring substituted 6-deoxytetracyclines
US3824285A (en) 1967-09-13 1974-07-16 Pfizer 4-oxo-4-dedimethylaminotetracycline-4,6-hemiketals
US3947517A (en) 1969-06-12 1976-03-30 Research Corporation Stereoselective introduction of tetracyclines hydroxyl group at 12(a) position in synthesis of tetracyclines
DE2437487A1 (de) 1974-08-03 1976-02-19 Merck Patent Gmbh 7-methoxy-6-thia-tetracycline und verfahren zu ihrer herstellung
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
YU290176A (en) 1976-11-26 1982-05-31 Pliva Zagreb Process for preparing 4-dedimethylamino-4-arylsulfonamido-5a,6-anhydrotetracycline
US4935412A (en) 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4925833A (en) 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US4704383A (en) 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
USRE34656E (en) 1983-12-29 1994-07-05 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency
JP3016587B2 (ja) 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5308839A (en) 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
US5770588A (en) 1991-02-11 1998-06-23 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
US5231017A (en) 1991-05-17 1993-07-27 Solvay Enzymes, Inc. Process for producing ethanol
DK0536515T3 (da) 1991-10-04 2002-04-08 American Cyanamid Co Nye 7-substitueret-9-substitueret amino-6-demethyl-6-deoxytetracycliner
US5494903A (en) 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
USRE40183E1 (en) 1991-10-04 2008-03-25 Wyeth Holdings Corporation 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5258371A (en) 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
US6043225A (en) 1992-06-12 2000-03-28 Board Of Regents Of The University Of Washington Diagnosis and treatment of arterial chlamydial granuloma
SG47520A1 (en) 1992-08-13 1998-04-17 American Cyanamid Co New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
US5420272A (en) 1992-08-13 1995-05-30 American Cyanamid Company 7-(substituted)-8-(substituted)-9-](substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5442059A (en) 1992-08-13 1995-08-15 American Cyanamid Company 9-[(substituted glycyl)amido)]-6-demethyl-6-deoxytetracyclines
US5328902A (en) 1992-08-13 1994-07-12 American Cyanamid Co. 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5284963A (en) 1992-08-13 1994-02-08 American Cyanamid Company Method of producing 7-(substituted)-9-[(substituted glycyl)-amidol]-6-demethyl-6-deoxytetra-cyclines
JPH06256280A (ja) 1992-11-17 1994-09-13 Univ New York State 糖尿病における過度のコラーゲン架橋結合を阻害する非抗菌性化学修飾テトラサイクリンを含むテトラサイクリン
US6043231A (en) 1993-03-02 2000-03-28 The Research Foundation Of State Univ. Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5523297A (en) 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5371076A (en) 1993-04-02 1994-12-06 American Cyanamid Company 9-[(substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines
US5668122A (en) 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
WO1995022529A1 (en) 1994-02-17 1995-08-24 Pfizer Inc. 9-(substituted amino)-alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5843925A (en) 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5574026A (en) 1994-12-13 1996-11-12 American Cyanamid Company Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
US5834449A (en) 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
US5827840A (en) 1996-08-01 1998-10-27 The Research Foundation Of State University Of New York Promotion of wound healing by chemically-modified tetracyclines
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
US5773430A (en) 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US5929055A (en) 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
AU753370B2 (en) 1998-01-23 2002-10-17 Trustees Of Tufts College Pharmaceutically active compounds and methods of use thereof
US6277061B1 (en) 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US6914057B1 (en) 1998-09-28 2005-07-05 The Research Foundation Of State University Of New York Inhibitor of cataract formation
US5998390A (en) 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
EP1124558A4 (en) 1998-09-28 2004-10-27 Res Foundation Ofstate Univers NEW INHIBITANT AGAINST CATARACT EDUCATION
US6231894B1 (en) 1999-10-21 2001-05-15 Duke University Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
AU2000257445A1 (en) 2000-06-16 2002-01-02 Trustees Of Tufts College 7-n-substituted phenyl tetracycline compounds
BR0112265A (pt) 2000-07-07 2003-06-24 Tufts College Compostos de tetraciclina substituìda, e de sanciclina 7-substituìda, método para tratar um estado responsivo à tetraciclina em um indivìduo, e, composição farmacêutica
ATE504562T1 (de) 2000-07-07 2011-04-15 Tufts College 7-, 8- und 9-substitutierte tetracyclinverbindungen
CZ2003344A3 (cs) 2000-07-07 2003-05-14 Trustees Of Tufts College 9-Substituované minocyklinové sloučeniny
WO2002072532A1 (en) 2001-03-13 2002-09-19 Paratek Pharmaceuticals, Inc. 7, 9-substituted tetracycline compounds
EP1381372A2 (en) 2001-03-14 2004-01-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as synergistic antifungal agents
US6841546B2 (en) 2001-03-14 2005-01-11 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as antifungal agents
EP1399414B1 (en) 2001-04-24 2010-01-13 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
US8088820B2 (en) 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
US20060194773A1 (en) 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
EP1408987B1 (en) 2001-07-13 2013-04-10 Paratek Pharmaceuticals, Inc. Tetracycline compounds having target therapeutic activities
EP2311797A1 (en) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
JP2005526754A (ja) 2002-03-08 2005-09-08 パラテック ファーマシューティカルズ インコーポレイテッド アミノメチル置換されたテトラサイクリン化合物
EP1503981A4 (en) 2002-03-21 2007-08-15 Paratek Pharm Innc SUBSTITUTED TETRACYCLINE COMPOUNDS
WO2004006850A2 (en) 2002-07-12 2004-01-22 Paratek Pharmaceuticals, Inc 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS
JP4686189B2 (ja) 2002-10-24 2011-05-18 パラテック ファーマシューティカルズ インコーポレイテッド Ｒｎａを調節するための置換テトラサイクリン化合物の使用方法
WO2004038001A2 (en) 2002-10-24 2004-05-06 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
WO2005009943A2 (en) 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
WO2005082860A1 (en) 2004-02-27 2005-09-09 National Research Council Of Canada Tetracyclines and their use as calpain inhibitors
US7838524B2 (en) 2004-04-30 2010-11-23 Bayer Healthcare Llc Substituted pyrazolyl urea derivatives useful in the treatment of cancer
KR101171408B1 (ko) 2004-05-21 2012-08-08 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 테트라사이클린 및 이의 유사체의 합성
JP2008518025A (ja) 2004-10-25 2008-05-29 パラテック ファーマシューティカルズ インコーポレイテッド ４−アミノテトラサイクリンおよびその使用の方法
WO2006047756A2 (en) 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
AU2006210406C1 (en) 2005-02-04 2013-03-07 Paratek Pharmaceuticals, Inc. 11a, 12-derivatives of tetracycline compounds
CN101119964A (zh) 2005-02-15 2008-02-06 惠氏公司 9-经取代四环素
CA2616224A1 (en) 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
EP1991236A2 (en) 2006-01-24 2008-11-19 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
JP5335664B2 (ja) 2006-04-07 2013-11-06 プレジデント アンド フェロウズ オブ ハーバード カレッジ テトラサイクリンおよびその類似体の合成
WO2007133797A2 (en) 2006-05-15 2007-11-22 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
EP2479169B1 (en) 2006-10-11 2014-12-03 President and Fellows of Harvard College Synthesis of Enone Intermediate
WO2008045507A2 (en) 2006-10-11 2008-04-17 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of bacillus anthracis infections
IL270446B2 (en) 2006-12-21 2023-10-01 Paratek Pharm Innc A tetracycline compound, a pharmaceutical preparation containing the tetracycline compound, and the tetracycline compound or the pharmaceutical preparation for the treatment of the tetracycline-responsive condition
EP2144614A1 (en) 2007-04-12 2010-01-20 Paratek Pharmaceuticals, Inc. Methods for treating spinal muscular atrophy using tetracycline compounds
WO2009009042A1 (en) 2007-07-06 2009-01-15 Paratek Pharmaceuticals, Inc. Methods for synthesizing substituted tetracycline compounds
WO2009073056A1 (en) 2007-09-07 2009-06-11 Dr. Reddy's Laboratories Ltd. Novel tetracycline derivatives as antibacterial agents
JP2011517697A (ja) 2008-04-14 2011-06-16 パラテック ファーマシューティカルズ インコーポレイテッド 置換テトラサイクリン化合物
TWI585071B (zh) * 2008-05-19 2017-06-01 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
US8338477B2 (en) 2008-07-11 2012-12-25 Neumedics Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits
HUE026562T2 (hu) 2008-08-08 2016-06-28 Tetraphase Pharmaceuticals Inc C7-fluor-helyettesített tetraciklin vegyületek
WO2010126607A2 (en) 2009-04-30 2010-11-04 President And Fellows Of Harvard College Synthesis of tetracyclines and intermediates thereto
US8367654B2 (en) 2009-05-08 2013-02-05 Tetraphase Pharmaceuticals, Inc. 8-AZA tetracycline compounds
CN102459153A (zh) 2009-05-08 2012-05-16 四相制药公司 四环素类化合物
US20120115819A1 (en) 2009-05-13 2012-05-10 Clark Roger B Pentacycline Compounds
EP2470500B1 (en) 2009-08-28 2017-10-04 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
US20120329761A1 (en) 2010-03-10 2012-12-27 University Health Network Use of tigecycline for treatment of cancer
WO2011123536A1 (en) 2010-03-31 2011-10-06 Tetraphase Pharmaceuticals, Inc. Polycyclic tetracycline compounds
WO2012021712A1 (en) 2010-08-12 2012-02-16 Tetraphase Pharmaceuticals, Inc. Tetracycline analogs
WO2012047907A1 (en) 2010-10-04 2012-04-12 President And Fellows Of Harvard College Synthesis of c5-substituted tetracyclines, uses thereof, and intermediates thereto
LT2707003T (lt) * 2011-05-12 2019-10-10 Paratek Pharmaceuticals, Inc. Kristalinės (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetrahidroksi-7-[(metoksi(metil)amino)-metil]-1,11-diokso-1,4,4a,5,5a,6,11,12a-oktahidro-naftacen-2-karboksirūgšties amido druskos ir jų panaudojimo būdai
TR201902057T4 (tr) 2012-08-31 2019-03-21 Tetraphase Pharmaceuticals Inc Tetrasiklin bileşikleri.
MA40836A (fr) 2014-10-23 2017-08-29 Tetraphase Pharmaceuticals Inc Procédures de semi-synthèse
WO2017097891A1 (en) * 2015-12-10 2017-06-15 Sandoz Ag Crystalline eravacycline
WO2017125557A1 (en) 2016-01-22 2017-07-27 Sandoz Ag Crystalline eravacycline bis-hydrochloride
MA46102A (fr) 2016-08-30 2019-07-10 Tetraphase Pharmaceuticals Inc Composés de tétracycline et méthodes de traitement
MA46567A (fr) * 2016-10-19 2019-08-28 Tetraphase Pharmaceuticals Inc Formes cristallines de l'éravacycline

Also Published As

Publication number Publication date
US12269807B2 (en) 2025-04-08
ES2978198T3 (es) 2024-09-06
JP2019531321A (ja) 2019-10-31
HUE066360T2 (hu) 2024-07-28
PH12019500822A1 (en) 2019-08-19
US20190256462A1 (en) 2019-08-22
US20260055070A1 (en) 2026-02-26
HRP20240605T1 (hr) 2024-07-19
KR20190065414A (ko) 2019-06-11
KR102880712B1 (ko) 2025-11-03
EP3529236A1 (en) 2019-08-28
SG11201903327PA (en) 2019-05-30
WO2018075767A1 (en) 2018-04-26
US11578044B2 (en) 2023-02-14
JP7598913B2 (ja) 2024-12-12
US20230416212A1 (en) 2023-12-28
JP2022186979A (ja) 2022-12-15
MA46567A (fr) 2019-08-28
US10961190B2 (en) 2021-03-30
CN110582486A (zh) 2019-12-17
CN117903083A (zh) 2024-04-19
DK3529236T3 (da) 2024-05-13
KR20240058958A (ko) 2024-05-07
PH12019500822B1 (en) 2024-02-21
KR102660864B1 (ko) 2024-04-25
PL3529236T3 (pl) 2024-07-08
SI3529236T1 (sl) 2024-08-30
US20210363103A1 (en) 2021-11-25
CN110582486B (zh) 2024-01-12
JP7492335B2 (ja) 2024-05-29
EP3529236B1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
EP3136857A4 (en) Crystalline form of baricitinib
IL257026A (en) Solid state forms of eluxadoline
SG10201913200XA (en) Crystalline form of lorlatinib free base
AU362779S (en) Wristwatch
IL246385B (en) Crystalline forms of efitinib di-malate
ZA201906464B (en) Crystalline forms of (s)-afoxolaner
SI3380554T1 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
IL265628A (en) Solid state forms of valbenazine
SG10202101979TA (en) Crystalline forms of c21h22ci2n4o2
PL3113773T3 (pl) Krystaliczne postaci grapiprantu
PL3529236T3 (pl) Krystaliczne formy erawacykliny
ZA201706282B (en) Solid forms of menaquinols
PL3532457T3 (pl) Postacie krystaliczne hydroksynorketaminy
IL270961A (en) Crystalline form of N-butyldeoxygalactonogirimycin
GB201419174D0 (en) Crystalline forms
IL265445A (en) crystalline forms
IL263673A (en) Solid state forms of spiro-oxindole compounds
IL253479A0 (en) Crystalline forms of efinconazole
PL3350179T3 (pl) Krystaliczne postacie
IL270937A (en) Crystalline forms of saltalicib
ZA201902553B (en) Crystalline forms
IL261795A (en) Crystalline form